Medline (NASDAQ:MDLN) Earns Overweight Rating from Analysts at Barclays

Analysts at Barclays began coverage on shares of Medline (NASDAQ:MDLN) in a report issued on Monday. The brokerage set an “overweight” rating and a $50.00 price target on the stock. Barclays‘s price target would suggest a potential upside of 23.40% from the stock’s current price.

Several other brokerages have also issued reports on MDLN. Stifel Nicolaus initiated coverage on shares of Medline in a report on Monday. They issued a “buy” rating and a $46.00 price target on the stock. The Goldman Sachs Group started coverage on shares of Medline in a research report on Monday. They set a “buy” rating and a $49.00 target price on the stock. TD Cowen began coverage on shares of Medline in a research note on Monday. They issued a “buy” rating and a $46.00 target price on the stock. Royal Bank Of Canada initiated coverage on shares of Medline in a research note on Monday. They set an “outperform” rating and a $47.00 price target for the company. Finally, BMO Capital Markets started coverage on Medline in a report on Monday. They set an “outperform” rating and a $45.00 price objective on the stock. Twenty-one investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Medline currently has a consensus rating of “Moderate Buy” and an average price target of $47.26.

Medline Price Performance

MDLN opened at $40.52 on Monday. Medline has a 1 year low of $34.89 and a 1 year high of $45.50.

Insider Buying and Selling at Medline

In other news, Director Andrew J. Mills bought 2,586,206 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was bought at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the completion of the purchase, the director owned 2,586,206 shares of the company’s stock, valued at approximately $74,999,974. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total value of $172,727,085.27. Following the completion of the transaction, the insider directly owned 4,806,160 shares in the company, valued at $136,350,759.20. The trade was a 55.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information.

Key Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Jefferies started coverage with a “Buy,” highlighting Medline’s ~$25 billion supply-chain scale as a durable competitive advantage that supports growth and margin expansion. Medline’s $25 bln supply chain scale wins Jefferies “buy” in coverage debut
• Positive Sentiment: TipRanks coverage of new sell‑side initiations (e.g., J.P. Morgan) emphasizes Medline’s prime‑vendor position, branded mix shift and margin expansion runway — factors analysts say justify a premium valuation. Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation
• Positive Sentiment: Multiple outlets report a broad set of bullish analyst initiations after the IPO (Buy/Overweight ratings and constructive price targets), which is amplifying positive sentiment and buying interest. Analysts initiate Medline with bullish ratings after blockbuster IPO
• Positive Sentiment: Media and TV coverage — including praise from commentators such as Jim Cramer — is raising retail and institutional visibility for MDLN, supporting near‑term momentum. Jim Cramer Medline: “It’s a Terrific Company”
• Neutral Sentiment: A valuation note points out shares are trading near a DCF estimate after the recent moves, suggesting limited near‑term upside unless execution or margin beats occur — a reminder that much of the positive view is already priced in. Medline (MDLN) Valuation Check As Shares Trade Near DCF Estimate After Recent Moves

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.